118 Demographics and Real World Healthcare Cost and Utilization for Patients With Probable Tardive Dyskinesia

AbstractBackgroundTardive dyskinesia (TD) is a movement disorder associated with prolonged exposure to antipsychotics. The current study was designed to describe demographics and comorbidities for patients with a dyskinesia diagnosis as probable TD (cohort 1), patients likely to have undiagnosed/uncoded TD (cohort 2), and a control population.MethodsThis retrospective study analyzed Medicaid claims data from July 2013-March 2017. For a pool of patients with a history of 3 months or more of taking an antipsychotic, three cohorts were evaluated: cohort 1 (ICD-9/10 codes for dyskinesia); cohort 2 (propensity score matching to cohort 1); and cohort 3 (patients withschizophrenia, major depressive disorder [MDD], and/or bipolar disorder [BD] and history of ≤2 antipsychotic medications). Outcomes included patient characteristics, Charlson Comorbity Index (CCI) and healthcare utilization (pre-and post [12-month] period).ResultsCohort sizes and characteristics were: cohort 1 (n=1,887; female, 68%; mean age, 42 years; MDD, 17%; BD, 48%); cohort 2 (n=1,572; female, 58%; mean age, 39 years; MDD, 22%; BD, 48%); cohort 3 (n=25,949; female, 67%; mean age, 40 years; MDD, 11%; BD, 49%). Cohorts 1 and 2 had higher comorbidity burden than cohort 3 (mean pre-index CCIs: 0.68, 0.79, and 0.47, respectively; p<0.001 for each cohort). After 12 months, mean per member per year healthcare costs were higher in cohort 1 and2 compared to cohort 3 ($21,293, $18,988, and $11,522, respectively), as were mean claims per member per year (185, 138, and 109, respectively).ConclusionIn the study population, patients likely suffering from TD, ICD-9/10 code-confirmed or unconfirmed, have a higher overall comorbidity burden and healthcareutilization than those who probably do not have TD.Funding AcknowledgementsThis study was funded by Neurocrine Biosciences, Inc.

Download Full-text

Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML)

Blood ◽

10.1182/blood-2018-99-111281 ◽

2018 ◽

Vol 132 (Supplement 1) ◽

pp. 3591-3591

Author(s):

Bruno C. Medeiros ◽

Sacha Satram-Hoang ◽

Faiyaz Momin ◽

Monika Parisi

Keyword(s):

Mortality Risk ◽

Survival Benefit ◽

Research Funding ◽

Claims Data ◽

Poor Performance ◽

Patient Characteristics ◽

Risk Of Death ◽

Elderly Aml ◽

Comorbidity Burden ◽

Receive Treatment

Abstract Introduction: The incidence of AML increases with age and more than half of patients are diagnosed at age ≥ 65 years. The prognosis of patients aged ≥ 65 years is very poor and worsens with advancing age as treatment efficacy and tolerability have been shown to deteriorate markedly with age. The objective of this analysis was to examine treatment trends over time, factors predictive of therapy receipt and prognosis, and overall survival in an elderly AML population in routine clinical practice. Methods: This retrospective analysis utilized linked cancer registry claims data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database from January 1, 2000 to December 31, 2013, with Medicare enrollment and claims data through 2015, thus allowing a minimum 2-year follow-up. Patients were included if they were diagnosed with a first primary AML cancer, were aged > 66 years, and continuously enrolled in Medicare Parts A and B with no health maintenance organization (HMO) coverage in the year prior to diagnosis. Differences in patient characteristics by treatment status were assessed with the chi-square test for categorical variables and analysis of variance (ANOVA) or t-test for continuous variables. Unadjusted Kaplan-Meier survival curves with accompanying log-rank test were generated. A time-varying Cox proportional hazards regression model examined the relative risk of death by treatment status, adjusting for age, sex, race, prior myelodysplastic syndromes (MDS), poor performance indicators (PPIs), comorbidity burden, income, education, marital status, year of diagnosis, and geographic region. Results: Of the 11,142 patients analyzed in the study, 4,772 (43%) patients received treatment with chemotherapy within 3 months of diagnosis and 6,370 (57%) patients did not receive treatment. Treatment rates increased over the study time period from 36% in 2000 to 55% in 2013 (P < 0.0001; Figure 1). The mean age at diagnosis was 75 years for treated patients and 80 years for untreated patients (P < 0.0001). Forty-three percent of treated patients were over the age of 75 years at diagnosis compared with 74% of untreated patients. Treated patients were more likely to be male (54% vs 50%), be married (60% vs 46%), to have a lower incidence of prior MDS (14% vs 19%), were less likely to have PPIs (8% vs 19%), and had a lower comorbidity burden (54% vs 43% with a comorbidity score of 0) compared with untreated patients. The median unadjusted overall survival was 2.13 months for the overall population and was longer for treated patients (5.3 months) compared with untreated patients (1.6 months; log-rank P < 0.0001). In multivariate survival analysis, treated patients exhibited a 14% lower risk of death compared with untreated patients (hazard ratio 0.86; 95% CI 0.81-0.91). Patients receiving treatment within 30 days of diagnosis had a 67% reduction in 30-day mortality risk and a 41% reduction in 60-day mortality risk compared with those who did not receive treatment. Advanced age, higher comorbidity score, presence of PPIs, and being unmarried were significantly associated with higher mortality risk. Conclusions: Use of chemotherapy among the elderly AML patient population has increased over time. However, at the time of the analysis, about 45% of patients were still not receiving treatment, and the rate of undertreatment was even more pronounced among those aged > 75 years. The use of antileukemic therapy was associated with a significant survival benefit compared with palliative care, after controlling for age, comorbidities, poor performance, and other patient characteristics. An unmet treatment need among older AML patients persists. Disclosures Satram-Hoang: Genentech: Research Funding; Celgene Corp.: Research Funding. Parisi:Celgene Corp.: Employment, Equity Ownership.

Download Full-text

142 The Burden of Tardive Dyskinesia Secondary to Antipsychotic Medication Use Among Patients With Mental Disorders

CNS Spectrums ◽

10.1017/s1092852918000378 ◽

2018 ◽

Vol 23 (1) ◽

pp. 88-89

Author(s):

Joseph McEvoy ◽

Tyson Park ◽

Traci Schilling ◽

Emi Terasawa ◽

Rajeev Ayyagari ◽

...

Keyword(s):

Tardive Dyskinesia ◽

Healthcare Resource Utilization ◽

Major Depressive ◽

Additional Burden ◽

Pharmaceutical Industries ◽

Psychiatric Conditions ◽

The Impact ◽

Cohort Change ◽

Funding Acknowledgements

AbstractIntroductionExtrapyramidal symptoms (EPS), including tardive dyskinesia (TD), may result from exposure to antipsychotics. TD is often irreversible, may be debilitating, and cause additional burden to patients with underlying psychiatric conditions.ObjectiveTo assess the impact of developing TD, both with and without other EPS, on healthcare resource utilization (HRU).MethodsData on patients receiving antipsychotics who had schizophrenia, major depressive disorder, or bipolar disorder were extracted from a Medicaid claims database. Patients from the TD cohorts (TD+EPS and TD non-EPS) were matched to those in the non-TD/EPS cohort at ∼1:5 ratio. HRU outcomes associated with TD were assessed.ResultsTD+EPS (n=289) and TD non-EPS (n=394) cohorts were matched with 1398 and 1922 control patients, respectively. The percentage of patients with all-cause and mental disorder-related inpatient admissions increased from baseline to follow-up in the TD+EPS (12.8% and 12.5%, respectively) and TD non-EPS (16.0% and 13.5%) cohorts, in contrast with slight decreases (∼3%) in matched controls. A higher percentage of patients in the TD cohorts had medical admissions/visits and claims for drugs that might be used to address TD or EPS than their matched controls at baseline and follow-up. The within-cohort change from baseline to follow-up in the use of potential drugs for TD or EPS was similar between the TD cohorts and their matched controls; however, both TD cohorts exhibited a larger increase in crisis–non-specific psychotherapy services versus matched controls.ConclusionsResults demonstrated increased HRU in TD patients with or without other pre-existing EPS, compared with matched controls.Presented at: Psych Congress; September 16–19, 2017; New Orleans, Louisiana, USA.Funding AcknowledgementsThis study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.

Download Full-text

Prevalence and natural history of pineal cysts in adults

Journal of Neurosurgery ◽

10.3171/2011.6.jns11506 ◽

2011 ◽

Vol 115 (6) ◽

pp. 1106-1114 ◽

Cited By ~ 48

Author(s):

Wajd N. Al-Holou ◽

Samuel W. Terman ◽

Craig Kilburg ◽

Hugh J. L. Garton ◽

Karin M. Muraszko ◽

...

Keyword(s):

Natural History ◽

Mr Imaging ◽

Demographic Data ◽

Patient Characteristics ◽

Initial Study ◽

Pineal Cyst ◽

History Analysis ◽

History Of ◽

Study Population

Object We reviewed our experience with pineal cysts to define the natural history and clinical relevance of this common intracranial finding. Methods The study population consisted of 48,417 consecutive patients who underwent brain MR imaging at a single institution over a 12-year interval and who were over 18 years of age at the time of imaging. Patient characteristics, including demographic data and other intracranial diagnoses, were collected from cases involving patients with a pineal cyst. We then identified all patients with pineal cysts who had been clinically evaluated at our institution and who had at least 6 months of clinical and imaging follow-up. All inclusion criteria for the natural history analysis were met in 151 patients. Results Pineal cysts measuring 5 mm or larger in greatest dimension were found in 478 patients (1.0%). Of these, 162 patients were male and 316 were female. On follow-up MR imaging of 151 patients with pineal cyst at a mean interval of 3.4 years from the initial study, 124 pineal cysts remained stable, 4 increased in size, and 23 decreased in size. Cysts that were larger at the time of initial diagnosis were more likely to decrease in size over the follow-up interval (p = 0.004). Patient sex, patient age at diagnosis, and the presence of septations within the cyst were not significantly associated with cyst change on follow-up. Conclusions Follow-up imaging and neurosurgical evaluation are not mandatory for adults with asymptomatic pineal cysts.

Download Full-text

Patients’ willingness to defer resection of diminutive polyps: results of a multicenter survey

Endoscopy ◽

10.1055/s-0043-121221 ◽

2017 ◽

Vol 50 (03) ◽

pp. 221-229 ◽

Cited By ~ 4

Author(s):

Daniel von Renteln ◽

Mickael Bouin ◽

Alan Barkun ◽

Audrey Weber ◽

Douglas Robertson ◽

...

Keyword(s):

Clinical Trial ◽

Cancer Risk ◽

Patient Characteristics ◽

Surveillance Colonoscopy ◽

Factors Associated ◽

Included Patient ◽

Multicenter Survey ◽

The Usa ◽

History Of ◽

Secondary Endpoints

Abstract Background and study aims Current colonoscopy practice requires removal of diminutive polyps. This is associated with costs, but the benefits to colorectal cancer (CRC) prevention remain unclear. The study aim was to understand patients’ willingness to defer resection of diminutive polyps and to examine the factors that influence patients’ decisions. Patients and methods Adults presenting for a colonoscopy were surveyed at three hospitals in the USA and Canada. Survey domains included: patient characteristics, risk perception, knowledge about CRC risk, willingness to defer polyp resection, and associated concerns. The primary endpoint was the proportion of patients who would be willing to participate in a clinical trial that deferred resection of diminutive polyps. Secondary endpoints included factors associated with willingness to defer diminutive polyp resection. Results 557 eligible individuals completed the survey (mean age 63; 61 % men), with 50 % of respondents being willing to participate in a randomized trial in which resection of diminutive polyps would be deferred until the next surveillance colonoscopy (95 % confidence interval [CI] 46 % – 55 %). Outside of a clinical trial, 57 % of participants would be agreeable to deferring resection of diminutive polyps (95 %CI 51 % – 63 %). Willingness to defer diminutive polyp resection was associated with higher education (P = 0.001), greater knowledge about cancer risk (P = 0.002), and a lower perception of cancer risk (all P < 0.001). Age, sex, income, a history of polyps, and a first-degree family member with CRC were not associated with willingness to defer diminutive polyp resection. Conclusions More than half of individuals undergoing a routine colonoscopy would be agreeable to deferring resection of diminutive polyps and participating in a trial to evaluate this approach.

Download Full-text

Effect of comorbidities and polypharmacy on fall risk among older adults

International Journal of Human and Health Sciences (IJHHS) ◽

10.31344/ijhhs.v6i1.380 ◽

2022 ◽

Vol 6 (1) ◽

pp. 75

Author(s):

Hand F Mahmoud ◽

Hebatullah EMZ Elmedany

Keyword(s):

Significant Positive Correlation ◽

Previous History ◽

The Elderly ◽

Positive Correlation ◽

Comorbidity Burden ◽

Increase Risk ◽

Risk Of Falls ◽

History Of ◽

Study Population ◽

Males And Females

Introduction: Fall is considered by far one of the leading causes of morbidity and mortality in the elderly population. Fall is almost always multifactorial. This study looks into the relation between different comorbidities, polypharmacy and falls.Methods: A descriptive and prospective study, the study population comprised 150 elderly patients aged > 60 years old, males and females, patients with previous history of falls are excluded. Comorbidity burden, polypharmacy and risk of falls were assessed.Results and Discussion: There was a significant positive correlation between Number of comorbidities, medications and risk of falls and there was a significant association between high risk of falls and presence of DM, PVD, OLD CVA and UI. Also, there was a significant positive correlation between age and risk of falls.Conclusion: Multiple comorbidities, polypharmacy and increasing age increase risk of falls.International Journal of Human and Health Sciences Vol. 06 No. 01 January’22 Page: 75-79

Download Full-text

KNOWLEDGE ABOUT THE STENTS AND POST PCI PHARMACOTHERAPY AMONG PATIENTS UNDERGOING PCI

Pakistan Heart Journal ◽

10.47144/phj.v54i2.2088 ◽

2021 ◽

Vol 54 (2) ◽

pp. 139-143

Author(s):

Ghulam Shabbir Shar ◽

Mukesh Kumar ◽

Haroon Ishaq ◽

Abdul Hakeem ◽

Bashir Ahmed Solangi ◽

...

Keyword(s):

Bypass Surgery ◽

Previous History ◽

Patient Characteristics ◽

Cross Sectional Study ◽

Single Patient ◽

Cross Sectional ◽

Adequate Knowledge ◽

Inadequate Knowledge ◽

History Of ◽

Study Population

Objectives: The main objective of the study was to evaluate the knowledge of patients for stents and post PCI pharmacotherapy. Methodology: A cross-sectional study was carried out on 102 consecutive selected patients with age ≥ 18 years who had undergone elective PCI. Various patient characteristics including demographics, previous history of cardiac problems, evaluation processes and overall knowledge were assessed using the survey questionnaire. With regards to evaluating levels of knowledge and awareness, the percentage for the number of correct answers about the dangers and advantages of elective PCI, clinical therapy for CAD, and bypass surgery was calculated. Results: A total of 102 patients were include, 78(76.5%) were male with mean age of study population was 53.93±11.0 years and majority 66(64.7%) were above 50 years of age. On analysis of demographics data it was observed that 74(72.5%) were educated. The results showed that adequate knowledge (≥70%) was observed only in 16.7% while there was not a single patient who answered all the questions in the correct fashion. Conclusion: Patients undergoing PCI had inadequate knowledge about the stents and post PCI pharmacotherapy.

Download Full-text

Temporal trends in utilization of transcatheter aortic valve implantation and patient characteristics – a nationwide cohort study

European Heart Journal ◽

10.1093/ehjci/ehaa946.2618 ◽

2020 ◽

Vol 41 (Supplement_2) ◽

Author(s):

J.E Strange ◽

C Sindet-Pedersen ◽

G Gislason ◽

C Torp-Pedersen ◽

E.L Fosboel ◽

...

Keyword(s):

Aortic Valve ◽

Transcatheter Aortic Valve Implantation ◽

Temporal Trends ◽

Patient Characteristics ◽

P Value ◽

Transcatheter Aortic Valve ◽

History Of ◽

Aortic Valve Implantation ◽

Valve Implantation ◽

First Time

Abstract Introduction In recent years, there has been a surge in the utilization of transcatheter aortic valve implantation (TAVI) for the treatment of severe symptomatic aortic stenosis. Randomized controlled trials have compared TAVI to surgical aortic valve replacement (SAVR) in patients at high-, intermediate-, and low perioperative risk. As TAVI continues to be utilized in patients with lower risk profiles, it is important to investigate the temporal trends in “real-world” patients undergoing TAVI. Purpose To investigate temporal trends in the utilization of TAVI and examine changes in patient characteristics of patients undergoing first-time TAVI. Methods Using complete Danish nationwide registries, we included all patients undergoing first-time TAVI between 2008 and 2017. To compare patient characteristics, the study population was stratified according to calendar year in the following groups: 2008–2009, 2010–2011, 2012–2013, 2014–2015, and 2016–2017. Results We identified 3,534 patients undergoing first-time TAVI. In 2008–2009, 180 patients underwent first-time TAVI compared with 1,417 patients in 2016–2017, resulting in a 687% increase in TAVI procedures performed. During the study period, the median age remained stable (2008–2009: Median age 82 year [25th–75th percentile: 78–85] vs. 2016–2017: Median age 81 years [25th–75th percentile: 76–85]; P-value: 0.06). The proportion of men undergoing first-time TAVI increased over the years (2008–2009: 49.4% vs 2016–2017: 54.9%; P-value for trend: <0.05), also the proportion with diabetes increased (2008–2009: 12.2% vs. 2016–2017: 19.3%; P-value for trend: <0.05). The proportion of patients with a history of stroke decreased over the years (2008–2009: 13.9% vs. 2016–2017: 12.1%; P-value for trend: <0.05). The same trend was seen in patients with a history of myocardial infarction (2008–2009: 24.4% vs. 2016–2017: 11.9%; P-value for trend: <0.05), ischaemic heart disease (2008–2009: 71.7% vs. 2016–2017: 29.4%; P-value for trend: <0.05), and heart failure (2008–2009: 45.6% vs. 2016–2017: 29.4%; P-value for trend: <0.05). Conclusions In this nationwide study, there was a marked increase in the utilization of TAVI in the years 2008–2017. Patients undergoing first-time TAVI had a decreasing comorbidity burden, while the age of the patients at first-time TAVI remained stable. Funding Acknowledgement Type of funding source: None

Download Full-text

Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment

Journal of Parkinson s Disease ◽

10.3233/jpd-202190 ◽

2021 ◽

pp. 1-12

Author(s):

Julie Chandler ◽

Radhika Nair ◽

Kevin Biglan ◽

Erin A. Ferries ◽

Leanne Munsie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Emergency Department ◽

Parkinson's Disease ◽

Cognitive Impairment ◽

Memory Loss ◽

Patient Characteristics ◽

Emergency Department Visits ◽

Administrative Claims ◽

Newly Diagnosed ◽

Comorbidity Burden

Background: Characterizing patients with Parkinson’s disease (PD) and cognitive impairment is important toward understanding their natural history. Objective: Understand clinical, treatment, and cost characteristics of patients with PD pre- and post-cognitive impairment (memory loss/mild cognitive impairment/dementia or dementia treatment) recognition. Methods: 2,711 patients with PD newly diagnosed with cognitive impairment (index) were identified using administrative claims data. They were matched (1:1) on age and gender to patients with PD and no cognitive impairment (controls). These two cohorts were compared on patient characteristics, healthcare resource utilization, and total median costs for 3 years pre- and post-index using Chi-square tests, t-tests, and Wilcoxon rank-sum tests. Logistic regression was used to identify factors predicting cognitive impairment. Results: Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index. Enrollment in Medicare Advantage Prescription Drug plans vs. commercial (OR = 1.60), dual Medicare/Medicaid eligibility (OR = 1.36), cerebrovascular disease (OR = 1.24), and PD medication use (OR = 1.46) were associated with a new cognitive impairment diagnosis (all p < 0.05). A greater proportion of patients with cognitive impairment had hospitalizations and emergency department visits and higher median total healthcare costs than controls for each year pre- and post-index. Conclusion: In patients with PD newly diagnosed with cognitive impairment, comorbidity burden, hospitalizations, emergency department visits, and total costs peaked 1-year pre- and post-identification. These data coupled with recommendations for annual screening for cognitive impairment in PD support the early diagnosis and management of cognitive impairment in order to optimize care for patients and their caregivers.

Download Full-text

Inappropriate outpatient antibiotic use in children insured by Kentucky Medicaid

Infection Control and Hospital Epidemiology ◽

10.1017/ice.2021.177 ◽

2021 ◽

pp. 1-7

Author(s):

Bethany A. Wattles ◽

Kahir S. Jawad ◽

Yana Feygin ◽

Maiying Kong ◽

Navjyot K. Vidwan ◽

...

Keyword(s):

Claims Data ◽

Inappropriate Prescribing ◽

Patient Characteristics ◽

Antibiotic Use ◽

Population Based ◽

Antibiotic Prescribing ◽

Cross Sectional ◽

Inappropriate Use ◽

Pharmacy Claims ◽

Medicaid Children

Abstract Objective: To describe risk factors associated with inappropriate antibiotic prescribing to children. Design: Cross-sectional, retrospective analysis of antibiotic prescribing to children, using Kentucky Medicaid medical and pharmacy claims data, 2017. Participants: Population-based sample of pediatric Medicaid patients and providers. Methods: Antibiotic prescriptions were identified from pharmacy claims and used to describe patient and provider characteristics. Associated medical claims were identified and linked to assign diagnoses. An existing classification scheme was applied to determine appropriateness of antibiotic prescriptions. Results: Overall, 10,787 providers wrote 779,813 antibiotic prescriptions for 328,515 children insured by Kentucky Medicaid in 2017. Moreover, 154,546 (19.8%) of these antibiotic prescriptions were appropriate, 358,026 (45.9%) were potentially appropriate, 163,654 (21.0%) were inappropriate, and 103,587 (13.3%) were not associated with a diagnosis. Half of all providers wrote 12 prescriptions or less to Medicaid children. The following child characteristics were associated with inappropriate antibiotic prescribing: residence in a rural area (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.07–1.1), having a visit with an inappropriate prescriber (OR, 4.15; 95% CI, 4.1–4.2), age 0–2 years (OR, 1.39; 95% CI, 1.37–1.41), and presence of a chronic condition (OR, 1.31; 95% CI, 1.28–1.33). Conclusions: Inappropriate antibiotic prescribing to Kentucky Medicaid children is common. Provider and patient characteristics associated with inappropriate prescribing differ from those associated with higher volume. Claims data are useful to describe inappropriate use and could be a valuable metric for provider feedback reports. Policies are needed to support analysis and dissemination of antibiotic prescribing reports and should include all provider types and geographic areas.

Download Full-text

Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Analyses from Two Long-Term Clinical Trials

CNS Spectrums ◽

10.1017/s1092852920002394 ◽

2021 ◽

Vol 26 (2) ◽

pp. 151-151

Author(s):

Stephen R. Marder ◽

Jean-Pierre Lindenmayer ◽

Chirag Shah ◽

Tara Carmack ◽

Angel S. Angelov ◽

...

Keyword(s):

Clinical Trials ◽

Adverse Events ◽

Tardive Dyskinesia ◽

Suicidal Behavior ◽

Prolonged Exposure ◽

First Occurrence ◽

Balance Disorder ◽

Clinical Interest ◽

Post Hoc

AbstractObjectiveTardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking agents. Long-term safety of the approved TD medication, valbenazine, was demonstrated in 2 clinical trials (KINECT 3 [NCT02274558], KINECT 4 [NCT02405091]). Data from these trials were analyzed post hoc to evaluate the onset and resolution of adverse events (AEs).MethodsParticipants in KINECT 3 and KINECT 4 received up to 48 weeks of once-daily valbenazine (40 or 80 mg). Data from these studies were pooled and analyzed to assess the incidence, time to first occurrence, and resolution for the following AEs of potential clinical interest: akathisia, balance disorder, dizziness, parkinsonism, somnolence/sedation, suicidal behavior/ideation, and tremor.ResultsIn the pooled population (N=314), all AEs of potential clinical interest occurred in <10% of participants, with somnolence (9.6%), suicidal behavior/ideation (6.4%), and dizziness (5.7%) being the most common AEs. Mean time to first occurrence ranged from 36 days (akathisia [n=9]) to 224 days (parkinsonism [n=2]). By end of study (or last study visit), resolution of AEs was as follows: 100% (suicidal ideation/behavior, parkinsonism); >85% (somnolence/sedation, dizziness); >70% (akathisia, balance disorder, tremor).ConclusionsIn long-term clinical trials, the incidence of AEs of potential clinical interest was low (<10%) and most were resolved by end of treatment (>70–100%). All patients taking valbenazine should be routinely monitored for AEs, particularly those that may exacerbate the motor symptoms associated with TD.FundingNeurocrine Biosciences, Inc.

Download Full-text